Table Of Content

Author Index Andersen, D.O., Weber, N.D., Wood, S.G., De Clercq, E., see De Castro, L.M., 101 Hughes, B.G., Murray, B.K. and North, J.A., De Clercq, E., see Gordon, Y.J., 11 In vitro virucidal activity of selected anthraqui- De Clercq, E., see Maudgal, P.C., 93 nones and anthraquinone derivatives, 185 De Clercq, E., see Naesens, L., 53 Andrei, G., see Snoeck, R., | De Clercq, E., see Neyts, J., 41 Andries, K., Dewindt, B., Snoeks, J., Willebrords, De Clercq, E., see Palu, G., 115 R., Stokbroekx, R. and Lewi, P.J., A compara- De Clercq, E., see Snoeck, R., 1 tive test of fifteen compounds against all known Del Gobbo, V., Foli, A., Balestra, E., Villani, N., human rhinovirus serotypes as a basis for a more Marini, S., Perno, C.F. and Calio, R., Immuno- rational screening program (Mini-Review), 213 modulatory activity of phosphonylmethoxyethyl Andries, K., see White, E.L., 255 adenine (PMEA), a potent anti-HIV nucleoside Ankel, H., see Bader, Th., 341 analogue, on in vivo murine models, 65 Araullo-Cruz, T., see Gordon, Y.J., 11 Desforges, B., see Sinet, M., 163 Awan, A.R., see Field, H.J., 29 Dewindt, B., see Andries, K., 213 Drach, J.C., see Nassiri, M.R., 135 Bader, Th., Yamada, Y. and Ankel, H., Antiviral Duncan, I.B., see Craig, J.C., 295 activity of the prostanoid clavulone II against Dutschman, G.E., see Kaufman, H.E., 225 vesicular stomatitis virus, 341 Balestra, E., see Del Gobbo, V., 65 Ebner, J.P., see Hoover, E.A., 77 Balzarini, J., see Naesens, L., 53 Eiseman, J.L., Yetter, R.A., Fredrickson, T.N., Balzarini, J., see Neyts, J., 41 Shapiro, 8.G., MacAuley, C. and Bilello, J.A., Balzarini, J., see Palu, G., 115 Effect of 3’azidothymidine administered in Bilello, J.A., see Eiseman, J.L., 307 drinking water or by continuous infusion on Birch, G.M., see Nassiri, M.R., 135 the development of MAIDS, 307 Bobek, M., see Kaufman, H.E., 225 Erzurum, S., see Gordon, Y.J., 11 Bohm, R., see Soike, K.F., 17 Buckheit, Jr., R.W., see White, E.L., 255 Field, H.J., Awan, A.R. and de la Fuente, R., Isolation of equine herpesvirus-1 mutants in the Calio, R., see Del Gobbo, V., 65 presence of (S)-9-(3-hydroxy-2-phosphonyl- Carpendale, M.T.F. and Freeberg, J.K., Ozone methoxypropyl)adenine: demonstration of resis- inactivates HIV at noncytotoxic concentrations, tance in vitro and in vivo, 29 279 Foli, A., see Del Gobbo, V., 65 Ceruzzi, M., see Kmetz, M.E., 173 Fredrickson, T.N., see Eiseman, J.L., 307 Cheng, Y.C., see Kaufman, H.E., 225 Freeberg, J.K., see Carpendale, M.T.F., 279 Chirigos, M.A., see White, E.L., 255 de la Fuente, R., see Field, H.J., 29 Clausen, H., see Hansen, J.-E.S., 231 Fukuma, M., Seto, Y. and Yamase, T., In vitro Cohen, J.S., Antisense oligodeoxynucleotides as antiviral activity of polyoxotungstate (PM-19) antiviral agents (Mini-Review), 121 and other polyoxometalates against herpes Coleman, L.A., see Nassiri, M.R., 135 simplex virus, 327 Colin, J.-N., see Sinet, M., 163 Craig, J.C., Duncan, I.B., Hockley, D., Grief, C., Gangemi, J.D., see De Castro, L.M., 101 Roberts, N.A. and Mills, J.S., Antiviral proper- Germany, J.M., see White, E.L., 255 ties of Ro 31-8959, an inhibitor of human Ghaffar, A., see De Castro, L.M., 101 immunodeficiency virus (HIV) proteinase, 295 Gordon, Y.J., Romanowski, E., Araullo-Cruz, T., Seaberg, L., Erzurum, S., Tolmam, R. and De De Castro, L.M., Kern, E.R., De Clercq, E., Clercq, E., Inhibitory effect of (S)-HPMPC, (S)- Ghaffar, A., Mayer, E.P., Vogt, P.E. and HPMPA, and 2’-nor-cyclic GMP on clinical Gangemi, J.D., Phosphonylmethoxyalkyl pur- ocular adenoviral isolates is serotype-dependent ine and pyrimidine derivatives for treatment of in vitro, 11 opportunistic cytomegalovirus and herpes sim- Grief, C., see Craig, J.C., 295 plex virus infections in murine AIDS, 101 362 Hansen, J.-E.S., Nielsen, C., Clausen, H., Mathie- the prophylaxis of retrovirus infection in vivo, 53 sen, L.R. and Nielsen, J.O., Effect of anti- Nakashima, H., see Otake, T., 241 carbohydrate antibodies on HIV infection in a Nassiri, M.R., Turk, S.R., Birch, G.M., Coleman, monocytic cell line (U937), 231 L.A., Hudson, J.L., Pudlo, J.S., Townsend, L.B. Hitchcock, M.J.M., see Soike, K.F., 17 and Drach, J.C., Activity of acyclic halogenated Hockley, D., see Craig, J.C., 295 tubercidin analogs against human cytomegalo- Holliday, J. and Williams, M.V., Inhibition of virus and in uninfected cells, 135 herpes simplex virus types 1 and 2 replication in Neyts, J., Snoeck, R., Balzarini, J. and De Clercq, vitro by mercurithio analogs of deoxyuridine, E., Particular characteristics of the anti-human 197 cytomegalovirus activity of (S)-1-(3-hydroxy-2- Hoover, E.A., Ebner, J.P., Zeidner, N.S. and phosphonylmethoxypropyl)cytosine (HPMPC) Mullins, J.I., Early therapy of feline leukemia in vitro, 41 virus infection (FeLV-FAIDS) with 9-(2-phos- Neyts, J., see Snoeck, R., 1 phonylmethoxyethyl)adenine (PMEA), 77 Nicholas, J.A., see Rubino, K.L., 265 Huang, J.-L., see Soike, K.F., 17 Nielsen, C., see Hansen, J.-E.S., 231 Hudson, J.L., see Nassiri, M.R., 135 Nielsen, J.O., see Hansen, J.-E.S., 231 Hughes, B.G., see Andersen, D.O., 185 Nokta, M.A., see Shafik, H.M., 205 North, J.A., see Andersen, D.O., 185 Janssen, P.A.J., see White, E.L., 255 Otake, T., Miyano, K., Mori, H., Morimoto, M., Kaufman, H.E., Varnell, E.D., Cheng, Y.C., Ueba, N., Kunita, N., Nakashima, H. and Bobek, M., Thompson, H.W. and Dutschman, Kurimura, T., Anti-HIV-1 activity of sulfated G.E., Suppression of ocular herpes recurrences amphotericin B in vitro, 241 by a thymidine kinase inhibitor in squirrel monkeys, 225 Palu, G., Stefanelli, S., Rassu, M., Parolin, C., Kern, E.R., see De Castro, L.M., 101 Balzarini, J. and De Clercq, E., Cellular uptake Kmetz, M.E., Ceruzzi, M. and Schwartz, J., of phosphonylmethoxyalkylpurine derivatives Vmw65 phosphorothioate oligonucleotides inhi- (Short Communication), 115 bit HSV KOS replication and Vmw65 protein Pancheva, S.N., Potentiating effect of ribavirin on synthesis, 173 the anti-herpes activity of acyclovir, 151 Kunita, N., see Otake, T., 241 Parolin, C., see Palu, G., 115 Kurimura, T., see Otake, T., 241 Pauwels, R., see White, E.L., 255 Perno, C.F., see Del Gobbo, V., 65 Launay, O., see Sinet, M., 163 Pocidalo, J.-J., see Sinet, M., 163 Lewi, P.J., see Andries, K., 213 Pollard, R.B., see Shafik, H.M., 205 Pudlo, J.S., see Nassiri, M.R., 135 MacAuley, C., see Eiseman, J.L., 307 Marini, S., see Del Gobbo, V., 65 Rassu, M., see Palu, G., 115 Martin, J.C., see Soike, K.F., 17 Roberts, N.A., see Craig, J.C., 295 Mathiesen, L.R., see Hansen, J.-E.S., 231 Romanowski, E., see Gordon, Y.J., 11 Maudgal, P.C. and De Clercq, E., Effects of Ross, L.J., see White, E.L., 255 phosphonylmethoxyyalkyl-purine and -pyrimi- Rubino, K.L., Tarpley, W.G. and Nicholas, J.A., dine derivatives on TK+ and TK— HSV-1 Effects of a soluble CD4 and CD4-Pseudomonas keratitis in rabbits, 93 exotoxin A chimeric protein on human periph- Mayer, E.P., see De Castro, L.M., 101 eral blood lymphocytes: lymphocyte activation Mills, J.S., see Craig, J.C., 295 and anti-HIV activity in vitro, 265 Miyano, K., see Otake, T., 241 Mori, H., see Otake, T., 241 Schols, D., see Snoeck, R., 1 Morimoto, M., see Otake, T., 241 Schwartz, J., see Kmetz, M.E., 173 Mullins, J.I., see Hoover, E.A., 77 Seaberg, L., see Gordon, Y.J., 11 Murray, B.K., see Andersen, D.O., 185 Seto, Y., see Fukuma, M., 327 Shafik, H.M., Nokta, M.A. and Pollard, R.B., Naesens, L., Balzarini, J. and De Clercq, E., Single- Recombinant human interferon beta ser protects dose administration of 9-(2-phosphonylmethox- against zidovudine-induced genetic damage in yethyl)jadenine (PMEA) and 9-(2-phosphonyl- AIDS patients, 205 methoxyethyl)-2,6-diaminopurine (PMEDAP) in Shannon, W.M., see White, E.L., 255 Shapiro, S.G., see Eiseman, J.L., 307 Turk, S.R., see Nassiri, M.R., 135 Sinet, M., Desforges, B., Launay, 0., Colin, J.-N. and Pocidalo, J.-J., Factors influencing zidovu- Ueba, N., see Otake, T., 241 dine efficacy when administered at early stages of Friend virus infection in mice, 163 Varnell, E.D., see Kaufman, H.E., 225 Snoeck, R., Schols, D., Andrei, G., Neyts, J. and Villani, N., see Del Gobbo, V., 65 De Clercq, E., Antiviral activity of anti-cytome- Vogt, P.E., see De Castro, L.M., 101 galovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridiza- Weber, N.D., see Andersen, D.O., 185 tion technique, | White, E.L., Buckheit, Jr., R.W., Ross, L.J., Snoeck, R., see Neyts, J., 41 Germany, J.M., Andries, K., Pauwels, R., Snoeks, J., see Andries, K., 213 Janssen, P.A.J., Shannon, W.M. and Chirigos, Soike, K.F., Huang, J.-L., Zhang, J.-Y., Bohm, R.., M.A., A TIBO derivative, R82913, is a potent Hitchcock, M.J.M. and Martin, J.C., Evaluation inhibitor of HIV-1 reverse transcriptase with of infrequent dosing regimens with (S)-1-[3- heteropolymer templates, 255 hydroxy-2-(phosphonylmethoxy)propyl]cytosine Willebrords, R., see Andries, K., 213 (S-HPMPC) on simian varicella infection in Williams, M.V., see Holliday, J., 197 monkeys, 17 Wood, S.G., see Andersen, D.O., 185 Stefanelli, S., see Palu, G., 115 Stokbroekx, R., see Andries, K., 213 Yamada, Y., see Bader, Th., 341 Yamase, T., see Fukuma, M., 327 Tarpley, W.G., see Rubino, K.L., 265 Yetter, R.A., see Eiseman, J.L., 307 Thompson, H.W., see Kaufman, H.E., 225 Tolmam, R., see Gordon, Y.J., 11 Zeidner, N.S., see Hoover, E.A., 77 Townsend, L.B., see Nassiri, M.R., 135 Zhang, J.-Y., see Soike, K.F., 17 Subject Index AIDS, Human immunodeficiency virus type | rolopyrimidine, Nucieoside, 135 (HIV-1), Sulfated amphotericin B, Amphoteri- 7-Deaza adenosine, Cytomegalovirus, Herpes, Pyr- cin B methyl ester, 243 rolopyrimidine, Nucleoside, 135 AIDS, Soluble CD4, sCD4-183, sCD4-PE40, HIV, Pseudomonas exotoxin A, 267 DNA hybridization, Human cytomegalovirus, Flow AIDS, ZDV, Interferon beta, Chromosomal da- cytometry, | mage, 205 DNA integrity, Cytomegalovirus, HPMPC, 41 AZT, Animal model of HIV infection, Friend virus, Dendritic keratitis, Herpes simplex virus, Recurrent Chemoprophylaxis, 163 ocular herpetic disease, Thymidine kinase, Virus Acyclovir, Ribavirin, Combination chemotherapy, inhibitor, 225 HSV-1, PRV, Keratitis, 151 Drug development, Antisense, Oligonucleotide, Adenovirus, (S)-HPMPC, (S)-HPMPA, 2’-nor-cyc- Translation arrest, Transcription arrest, 121 lic GMP, 11 dUTPase, Herpes simplex virus, Mercurithio- Amphotericin B methyl ester, Human immunodefi- deoxyuridine analog, 197 ciency virus type | (HIV-1), Sulfated amphotericin B, AIDS, 243 Emodin, Anthraquinone, Hypericin, Virucidal, Animal model of HIV infection, AZT, Friend virus, Tween-80, 185 Chemoprophylaxis, 163 Endocytosis, HPMPA, PMEA, Cellular uptake, Anthraquinone, Hypericin, Emodin, Virucidal, Nucleoside transport, 115 Tween-80, 185 Equine herpesvirus-1, EHV-1, Resistance, Phospho- Antibody-dependent enhancement, HIV, U937, Neu- nyl, Nucleoside analog, Chemotherapy, 29 tralization, Carbohydrate, 231 Antiherpetic agent, Polyoxometalate, PM-19, Keg- FeLV-FAIDS, Feline leukemia virus, 9-(2-Phos- gin-type structure, 327 phonylmethoxyethyl)adenine (PMEA), Immuno- Antisense, Drug development, Oligonucleotide, deficiency, Retrovirus, 78 Translation arrest, Transcription arrest, 121 Feline leukemia virus, 9-(2-Phosphonylmethoxye- Antiviral therapy, Azidothymidine, Zidovudine, thyl)adenine (PMEA), Immunodeficiency, Ret- MAIDS, LP-BM5, MuLV, 307 rovirus, Fe_LV-FAIDS, 78 Azidothymidine, Zidovudine, MAIDS, Antiviral Flow cytometry, Human cytomegalovirus, DNA therapy, LP-BMS, MuLV, 307 hybridization, | Friend virus, AZT, Animal model of HIV infection, BVDU, HSV-1 keratitis, TK— HSV-1, HPMPA, Chemoprophylaxis, 163 HPMPC, PMEA, Phosphonylmethoxyalkyl derivative, 93 HIV, Human immunodeficiency virus, Moloney murine sarcoma virus, MSV, Single dose admin- Carbohydrate, HIV, U937, Neutralization, Anti- istration, 53 body-dependent enhancement, 231 HIV, Ozone, Noncytotoxic, Virus inhibitor, 279 Cellular uptake, HPMPA, PMEA, Endocytosis, HIV, Proteinase, Inhibitor, 295 Nucleoside transport, 115 HIV, Soluble CD4, sCD4-183, sCD4-PE40, AIDS, Chemoprophylaxis, AZT, Animal model of HIV Pseudomonas exotoxin A, 265 infection, Friend virus, 163 HIV, U937, Neutralization, Antibody-dependent Chemotherapy, Equine herpesvirus-1, EHV-1, Re- enhancement, Carbohydrate, 231 sistance, Phosphonyl, Nucleoside analog, 29 HIV-1, TIBO, HIV-2, Reverse transcriptase, Novel Chromosomal damage, ZDV, Interferon beta, RNA template, 255 AIDS, 205 HIV-2, TIBO, HIV-1, Reverse transcriptase, Novel Clavulone, Vesicular stomatitis virus, Prostaglan- RNA template, 255 din, 341 HPMPA, HSV-1 keratitis, TK— HSV-1, BVDU, Combination chemotherapy, Acyclovir, Ribavirin, HPMPC, PMEA, Phosphonylmethoxyalkyl de- HSV-1, PRV, Keratitis, 151 rivative, 93 Cytomegalovirus, HPMPC, DNA integrity, 41 HPMPA, PMEA, Cellular uptake, Endocytosis, Cytomegalovirus, Herpes, 7-Deaza adenosine, Pyr- Nucleoside transport, 115 366 HPMPC therapy, Murine acquired immunodefi- therapy, LP-BM5, MuLV, 307 ciency syndrome, MAIDS, Opportunistic infec- MAIDS, Murine acquired immunodeficiency syn- tion, PMEA therapy, 102 drome, Opportunistic infection, HPMPC ther- HPMPC, Cytomegalovirus, DNA integrity, 41 apy, PMEA therapy, 102 HPMPC, HSV-1 keratitis, TK— HSV-1, BVDU, MSV, Human immunodeficiency virus, HIV, HPMPA, PMEA, Phosphonylmethoxyalky] de- Moloney murine sarcoma virus, Single dose rivative, 93 administration, 53 HPMPC, Simian varicella virus, Monkey, 17 Mercurithio-deoxyuridine analog, Herpes simplex HSV-1 keratitis, TK — HSV-1, BVDU, HPMPA, virus, d(UTPase, 197 HPMPC, PMEA, Phosphonylmethoxyalkyl de- Moloney murine sarcoma virus, Human immunode- rivative, 93 ficiency virus, HIV, MSV, Single dose adminis- HSV-1, Acyclovir, Ribavirin, Combination chemo- tration, 53 therapy, PRV, Keratitis, 151 Monkey, Simian varicella virus, HPMPC, 17 Herpes simplex virus, dUTPase, Mercurithio-deox- MuLV, Azidothymidine, Zidovudine, MAIDS, yuridine analog, 197 Antiviral therapy, LP-BM5, 307 Herpes simplex virus, Dendritic keratitis, Recurrent Murine acquired immunodeficiency syndrome, ocular herpetic disease, Thymidine kinase, Virus MAIDS, Opportunistic infection, HPMPC ther- inhibitor, 225 apy, PMEA therapy, 102 Herpes, Cytomegalovirus, 7-Deaza adenosine, Pyrrolopyrimidine, Nucleoside, 135 NK cytotoxicity, Nucleoside analog, 9-(2-phospho- Human cytomegalovirus, DNA hybridization, Flow nylmethoxyethyl)adenine, Interferon, Interleu- cytometry, | kin-1, Interleukin-2, 65 Human immunodeficiency virus, HIV, Moloney Neutralization, HIV, U937, Antibody-dependent murine sarcoma virus, MSV, Single dose admin- enhancement, Carbohydrate, 231 istration, 53 Noncytotoxic, HIV, Ozone, Virus inhibitor, 279 Human immunodeficiency virus type 1 (HIV-1), Novel RNA template, TIBO, HIV-1, HIV-2, Sulfated amphotericin B, Amphotericin B Reverse transcriptase, 255 methyl ester, AIDS, 243 Nucleoside analog, Equine herpesvirus-1, EHV-1, Hypericin, Anthraquinone, Emodin, Virucidal, Resistance, Phosphonyl, Chemotherapy, 29 Tween-80, 185 Nucleoside analog, 9-(2-phosphonylmethoxyethyl)adenine, NK cytotoxicity, Interferon, Inter- Immunodeficiency, Feline leukemia virus, 9-(2- leukin-1, Interleukin-2, 65 Phosphonylmethoxyethyl)adenine (PMEA), Ret- Nucleoside transport, HPMPA, PMEA, Cellular rovirus, Fe_LV-FAIDS, 78 uptake, Endocytosis, 115 Inhibitor, HIV, Proteinase, 295 Nucleoside, Cytomegalovirus, Herpes, 7-Deaza Interferon, Nucleoside analog, 9-(2-phosphonylme- adenosine, Pyrrolopyrimidine, 135 thoxyethyl)adenine, NK cytotoxicity, Interleu- kin-1, Interleukin-2, 65 Oligodeoxynucleotide, Phosphorothioate modifica- Interferon beta, ZDV, Chromosomal damage, tion, Protein synthesis inhibition, Replication AIDS, 205 inhibition, 173 Interleukin-1, Nucleoside analog, 9-(2-phosphonyl- Oligonucleotide, Antisense, Drug development, methoxyethyl)adenine, NK cytotoxicity, Inter- Translation arrest, Transcription arrest, 121 feron, Interleukin-2, 65 Opportunistic infection, Murine acquired immuno- Interleukin-2, Nucleoside analog, 9-(2-phosphonyl- deficiency syndrome, MAIDS, HPMPC therapy, methoxyethyl)adenine, NK cytotoxicity, Inter- PMEA therapy, 102 feron, Interleukin-1, 65 Ozone, HIV, Noncytotoxic, Virus inhibitor, 279 Keratitis, Acyclovir, Ribavirin, Combination che- 9-(2-Phosphonylmethox yethyl)adenine (PMEA), Fe- motherapy, HSV-1, PRV, 15i line leukemia virus, Immunodeficiency, Retro- Keggin-type structure, Polyoxometalate, PM-19, virus, FeLV-FAIDS, 78 Antiherpetic agent, 327 9-(2-phosphonylmethoxyethyl)adenine, Nucleoside analog, NK cytotoxicity, Interferon, Interleu- LP-BMS5, Azidothymidine, Zidovudine, MAIDS, kin-1, Interleukin-2, 65 Antiviral therapy, MuLV, 307 PM-19, Polyoxometalate, Keggin-type structure, MAIDS, Azidothymidine, Zidovudine, Antiviral Antiherpetic agent, 327 367 PMEA therapy, Murine acquired immunodeficien- Screening, antiviral, Rational screening program, cy syndrome, MAIDS, Opportunistic infection, Rhinovirus, 213 HPMPC therapy, 102 (S)-HPMPA, 2’-nor-cyclic GMP, (S)-HPMPC, PMEA, HPMPA, Cellular uptake, Endocytosis, Adenovirus, | 1 Nucleoside transport, 115 (S)-HPMPC, (S)-HPMPA, 2’-nor-cyclic GMP, PMEA, HSV-1 keratitis, TK— HSV-1, BVDU, Adenovirus, 11 HPMPA, HPMPC, Phosphonylmethoxyalkyl sCD4-183, Soluble CD4, sCD4-PE40, AIDS, HIV, derivative, 93 Pseudomonas exotoxin A, 265 PRV, Acyclovir, Ribavirin, Combination chemo- sCD4-PE40, Soluble CD4, sCD4-183, AIDS, HIV, therapy, HSV-1, Keratitis, 151 Pseudomonas exotoxin A, 265 Phosphonyl, Equine herpesvirus-1, EHV-1, Resis- Simian varicella virus, HPMPC, Monkey, 17 tance, Nucleoside analog, Chemotherapy, 29 Single dose administration, Human immunodefi- Phosphonyimethoxyalkyl derivative, HSV-1 kerati- ciency virus, HIV, Moloney murine sarcoma tis, TK— HSV-1, BVDU, HPMPA, HPMPC, virus, MSV, 53 PMEA, 93 Soluble CD4, sCD4-183, sCD4-PE40, AIDS, HIV, Phosphorothioate modification, Oligodeoxynucleo- Pseudomonas exotoxin A, 265 tide, Protein synthesis inhibition, Replication Sulfated amphotericin B, Human immunodeficiency inhibition, 173 virus type 1 (HIV-1), Amphotericin B methyl Polyoxometalate, PM-19, Keggin-type structure, ester, AIDS, 243 Antiherpetic agent, 327 Prostaglandin, Vesicular stomatitis virus, Clavu- TIBO, HIV-1, HIV-2, Reverse transcriptase, Novel lone, 341 RNA template, 255 Protein synthesis inhibition, Phosphorothioate mod- TK— HSV-1, HSV-1 keratitis, BVDU, HPMPA, ification, Oligodeoxynucleotide, Replication in- HPMPC, PMEA, Phosphonylmethoxyalkyl de- hibition, 173 rivative, 93 Proteinase, HIV, Inhibitor, 295 Thymidine kinase, Dendritic keratitis, Herpes Pseudomonas exotoxin A, Soluble CD4, sCD4-183, simplex virus, Recurrent ocular herpetic dis- sCD4-PE40, AIDS, HIV, 265 ease, Virus inhibitor, 225 Pyrrolopyrimidine, Cytomegalovirus, Herpes, 7- Transcription arrest, Antisense, Drug development, Deaza adenosine, Nucleoside, 135 Oligonucleotide, Translation arrest, 121 Translation arrest, Antisense, Drug development, Rational screening program, Rhinovirus, Screening, Oligonucleotide, Transcription arrest, 121 antiviral, 213 Tween-80, Anthraquinone, Hypericin, Emodin, Recurrent ocular herpetic disease, Dendritic kerati- Virucidal, 185 tis, Herpes simplex virus, Thymidine kinase, Virus inhibitor, 225 U937, HIV, Neutralization, Antibody-dependent Replication inhibition, Phosphorothioate modifica- enhancement, Carbohydrate, 231 tion, Oligodeoxynucleotide, Protein synthesis inhibition, 173 Vesicular stomatitis virus, Prostaglandin, Clavu- Resistance, Equine herpesvirus-1, EHV-1, Phos- lone, 341 phonyl, Nucleoside analog, Chemotherapy, 29 Virucidal, Anthraquinone, Hypericin, Emodin, Retrovirus, Feline leukemia virus, 9-(2-Phosphonyl- Tween-80, 185 methoxyethyl)adenine (PMEA), Immunodefi- Virus inhibitor, Dendritic keratitis, Herpes simplex ciency, Fe_LV-FAIDS, 78 virus, Recurrent ocular herpetic disease, Thymi- Reverse transcriptase, TIBO, HIV-1, HIV-2, Novel dine kinase, 225 RNA template, 255 Virus inhibitor, HIV, Ozone, Noncytotoxic, 279 Rhinovirus, Rational screening program, Screening, antiviral, 213 ZDV, Interferon beta, Chromosomal damage, Ribavirin, Acyclovir, Combination chemotherapy, AIDS, 205 HSV-1, PRV, Keratitis, 151 Zidovudine, Azidothymidine, MAIDS, Antiviral therapy, LP-BM5, MuLV, 307